Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Medisave Pharmaceuticals

Pharmaceutical manufacturer · Lahore · Pakistan

Lahore-based pharmaceutical manufacturer established to produce medicines for local and international markets.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date26 Jan 2026Newest effective date among published current price records
Corporate profile evidence3 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
501-A, Block-E, Saman Berg, Johar Town, Lahore, Pakistan
Phone
+92 42 35176016
Corporate source details checked
16 Aug 2026
Corporate profile completeness
75%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000681 Medisave Pharmaceuticals. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000681 120 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx120public portfolio records represented
REG108unique registrations represented
IDX118indexed MedInfoBase presentations
SRC2additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR117current validated price records
G53generic molecules in indexed catalogue
DF7dosage-form groups
TA11therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage98%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage91%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMedisave PharmaceuticalsShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medisave-pharmaceuticalsGenerated 23 Sep 2026Anti-infectives65 · 55%CNS & mental health16 · 14%Gastrointestinal & hepatology9 · 8%Pain & musculoskeletal5 · 4%Cardiovascular5 · 4%Hematology & thrombosis5 · 4%Respiratory & allergy4 · 3%Other therapeutic areas9 · 8%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMedisave PharmaceuticalsDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medisave-pharmaceuticalsGenerated 23 Sep 2026118presentationsTablet43 · 36%Injection36 · 31%Capsule15 · 13%Suspension11 · 9%Infusion8 · 7%Solution3 · 3%Other forms2 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionMedisave PharmaceuticalsCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medisave-pharmaceuticalsGenerated 23 Sep 2026107comparable productsBelow peer median46 · 43%Near peer median48 · 45%Above peer median13 · 12%Company median price position-4.7%Lowest-price equivalents14Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMedisave PharmaceuticalsCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medisave-pharmaceuticalsGenerated 23 Sep 2026Neutro Pharma (Pvt.) Ltd.,36 shared68% overlapNabiqasim Industries (Pvt) Ltd.,34 shared64% overlapM/s. Genix Pharma (Pvt) Ltd.33 shared62% overlapBosch Pharmaceuticals (Pvt) Ltd.32 shared60% overlapHIGH-Q Pharmaceuticals30 shared57% overlapEpharm Laboratories30 shared57% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives65 products · 55%
CNS & mental health16 products · 14%
Gastrointestinal & hepatology9 products · 8%
Pain & musculoskeletal5 products · 4%
Cardiovascular5 products · 4%
Hematology & thrombosis5 products · 4%
Respiratory & allergy4 products · 3%
Anesthesia & critical care3 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins15 products · 13%
Fluoroquinolone antibacterials10 products · 8%
Antimalarials8 products · 7%
Antiepileptics7 products · 6%
Macrolide antibacterials7 products · 6%
Analgesics / NSAIDs5 products · 4%
Oxazolidinone antibacterials5 products · 4%
Antivirals5 products · 4%
Formulation footprint

Dosage forms

Tablet43 products
Injection36 products
Capsule15 products
Suspension11 products
Infusion8 products
Solution3 products
Syrup2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 CexzoneCeftriaxone 5presentations 1000 mg, 250 mg, 500 mg · Injection #2 CiprozanCiprofloxacin 5presentations 200 mg/100 mL, 250 mg, 250 mg/5 mL, 500 mg · Infusion, Tablet, Suspension #3 LinzraoLinezolid 5presentations 100 mg/5 mL, 200 mg/100 mL, 600 mg, 600 mg/300 mL · Suspension, Infusion, Tablet #4 DiclosaveDiclofenac 4presentations 50 mg, 75 mg/3 mL · Tablet, Injection #5 DuloxisaveDuloxetine 4presentations 20 mg, 30 mg, 60 mg · Capsule, Tablet #6 MaczinAzithromycin 4presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Tablet, Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4643% of comparable products
Near market median48within ±5% of median
Above market median1312% of comparable products
Lowest-price equivalents14ties included
Company median price position -4.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Ribaxol 600 mgRibavirin · Tablet · 10's PKR 13.87/tablet-43.6% vs market median Medac 500 mgLevofloxacin · Tablet · 10's PKR 46.25/tablet-41.5% vs market median Anata 200 mgMetronidazole · Tablet · 20 x 10's PKR 1.29/tablet-39.6% vs market median Falcim 80 mg + 480 mgArtemether + Lumefantrine · Tablet · 2 x 8's PKR 72.49/tablet-33.5% vs market median Medac Medac 500 mg/100 mLLevofloxacin · IV infusion · 100ml PKR 4.62/mL-31.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 36shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 34shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 33shared generics Bosch Pharmaceuticals (Pvt) Ltd.258 products · 74 generics 32shared generics HIGH-Q Pharmaceuticals215 products · 61 generics 30shared generics Epharm Laboratories144 products · 67 generics 30shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers107Distinct registrations among indexed, published, presentation-validated products only
Verified price observations118
Products with a verified price118
Products with multiple price observations0
Source records with multiple versions115
Latest portfolio source check22 Sep 2026
Latest effective price date26 Jan 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

108 unique registration(s) · 118 indexed presentation(s) · 2 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
ABT-ZOLD Zoledronic acid 5 mg/100 mL Solution for infusion 1's 098400 PKR 29,423.22 PKR 29,423.22/vial/unit 19% below median
ABT-ZOLD Zoledronic acid 5 mg/100 mL Injection 1's 098400 PKR 29,423.22 PKR 29,423.22/vial/unit No comparator
Alusave Aluminium hydroxide + Magnesium hydroxide + Oxethazaine 291 mg + 98 mg + 10 mg/5 mL Suspension 120ml 068185 PKR 62.90 PKR 0.52/mL No comparator
Amisave 250/ml Amikacin 250 mg Injection 2ml Ampoule 114112 PKR 122.10 PKR 61.05/mL 7% below median
Anata Metronidazole 500 mg IV infusion 100ml 064753 PKR 180.99 PKR 1.81/mL Near median
Anata Metronidazole 200 mg Tablet 20 x 10's 068196 PKR 258.99 PKR 1.29/tablet 40% below median
Anata Metronidazole 400 mg Tablet 10 x 10's 068197 PKR 277.49 PKR 2.77/tablet 8% below median
Ascomed Ascorbic acid 500 mg Chewable tablet 40's 106042 PKR 55.50 PKR 1.39/tablet Near median
Ceftisav Cefotaxime 500 mg Injection 1's 064773 PKR 151.47 PKR 151.47/vial/unit Near median
Ceftisav Cefotaxime 250 mg Injection 1's 064774 PKR 100.50 PKR 100.50/vial/unit Near median
Ceftisav Cefotaxime 1000 mg Injection 1's 064775 PKR 272.44 PKR 272.44/vial/unit Near median
Cefusave Cefuroxime 750 mg Injection 1's 062581 PKR 184.99 PKR 184.99/vial/unit Near median
Cefusave Cefuroxime 1.5 g Injection 1's 062582 PKR 332.99 PKR 332.99/vial/unit Near median
Cesave Cefixime 100 mg/5 mL Suspension 30ml 068179 PKR 299.45 PKR 9.98/mL Near median
Cesave Cefixime 400 mg Capsule 5's 068180 PKR 536.59 PKR 107.32/capsule Near median
Cesave-200mg Cefixime 200 mg/5 mL Suspension 30ml 068178 PKR 366.45 PKR 12.22/mL 9% below median
Cexzone Ceftriaxone 250 mg IM injection 1's 062560 PKR 186.84 PKR 186.84/vial/unit Near median
Cexzone Ceftriaxone 500 mg Injection 1's 062561 PKR 314.49 PKR 314.49/vial/unit Near median
Cexzone Ceftriaxone 500 mg IV injection 1's 062562 PKR 314.49 PKR 314.49/vial/unit Near median
Cexzone Ceftriaxone 250 mg IV injection 1's 062567 PKR 186.84 PKR 186.84/vial/unit Near median
Cexzone Ceftriaxone 1000 mg Injection 1's 062568 PKR 593.83 PKR 593.83/vial/unit 7% below median
Ciprozan Ciprofloxacin 500 mg Tablet 10's 064776 PKR 397.73 PKR 39.77/tablet 7% below median
Ciprozan Ciprofloxacin 250 mg Tablet 10's 064777 PKR 240.49 PKR 24.05/tablet 5% below median
Ciprozan Ciprofloxacin 200 mg/100 mL IV infusion 100ml 092582 PKR 221.99 PKR 2.22/mL Near median
Ciprozan Ciprofloxacin 250 mg/5 mL Suspension 60ml 098108 PKR 295.99 PKR 4.93/mL Near median
Ciprozan Ciprofloxacin 250 mg/5 mL Suspension 120ml 098108 PKR 443.98 PKR 3.70/mL 29% below median
Conosave Fluconazole 150 mg Capsule 1's 064762 PKR 255.29 PKR 255.29/capsule Near median
Diclosave Diclofenac 75 mg/3 mL Injection 3ml x 5's 064749 PKR 120.25 PKR 8.02/mL Near median
Diclosave Diclofenac 75 mg/3 mL Injection 3ml x 10's 064749 PKR 234.94 PKR 7.83/mL Near median
Diclosave Diclofenac 75 mg/3 mL Injection 3ml x 100's 064749 PKR 2,308.71 PKR 7.70/mL Near median
Diclosave Diclofenac 50 mg Tablet 20's 068194 PKR 111.00 PKR 5.55/tablet Near median
Diclosave SR Diclofenac 100 mg Sustained-release tablet 20's 069034 PKR 184.99 PKR 9.25/tablet 43% below median
Dinsave Loratadine 10 mg Tablet 10's 062574 PKR 133.19 PKR 13.32/tablet 7% below median
Dinsave Loratadine 5 mg/5 mL Syrup 60ml 078810 PKR 90.65 PKR 1.51/mL 10% below median
Duloxisave Duloxetine 20 mg Capsule 14's 092586 PKR 826.92 PKR 59.07/capsule No comparator
Duloxisave Duloxetine 30 mg Capsule 28's 106263 PKR 2,042.32 PKR 72.94/capsule Near median
Duloxisave Duloxetine 30 mg Capsule 14's 106263 PKR 1,074.81 PKR 76.77/capsule 5% above median
Duloxisave Duloxetine 60 mg Enteric-coated tablet 10's 108234 PKR 1,276.45 PKR 127.65/tablet No comparator
Falcim Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 062583 PKR 488.38 PKR 61.05/tablet Near median
Falcim Artemether 80 mg/mL Injection 1ml x 5's 084068 PKR 887.97 PKR 177.59/mL 6% below median
Falcim Artemether + Lumefantrine 80 mg + 480 mg Tablet 2 x 8's 098107 PKR 1,159.91 PKR 72.49/tablet 34% below median
Falcim + Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 062584 PKR 591.98 PKR 37.00/tablet 7% below median
Falcim 80 Artemether + Lumefantrine 80 mg + 480 mg Tablet 1x 8's 098107 PKR 610.48 PKR 76.31/tablet 30% below median
Falcim dry Artemether + Lumefantrine 15 mg + 90 mg/5 mL Suspension 60ml 094547 PKR 332.99 PKR 5.55/mL 7% below median
Falcim dry Artemether + Lumefantrine 15 mg + 90 mg/5 mL Dry suspension 30ml 094547 PKR 191.47 PKR 6.38/mL 9% above median
Gabisave Pregabalin 50 mg Capsule 14's 094587 PKR 373.69 PKR 26.69/capsule 16% below median
Gabisave Pregabalin 75 mg Capsule 14's 094588 PKR 414.38 PKR 29.60/capsule 8% above median
Gabisave Pregabalin 150 mg Capsule 14's 094589 PKR 745.52 PKR 53.25/capsule 24% above median
Henk Piperacillin + tazobactam 2 g + 0.25 g IV injection 1's 117574 PKR 628.98 PKR 628.98/vial/unit Near median
Henk Piperacillin + tazobactam 4 g + 0.5 g IV injection 1's 117604 PKR 1,429.99 PKR 1,429.99/vial/unit 38% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Medisave Pharmaceuticals — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/medisave-pharmaceuticals/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.